Patrys kicks off RLS-2201 manufacturing with BioCina and FDA 505(b)(2) engagement, targeting Phase 0 trials in H2 2026.
Patrys Ltd (ASX:PAB) has begun manufacturing and regulatory activities for RLS-2201, its proprietary injectable quetiapine formulation being developed to treat delirium, as it works toward launching a ...
HotCopper on MSN
Patrys begins key activities for delirium candidate
Patrys (ASX:PAB) has started key manufacturing and regulatory activities for the advancement of RLS-2201, the company’s ...
現在アクセス不可の可能性がある結果が表示されています。
アクセス不可の結果を非表示にする